Catalent to Discuss the Benefits of ‘Ready-to-Market’ Formulations at SupplySide West
On Thursday, Oct. 17 at 2:30 p.m., Dr. Andrew Myers, Chief Science Advisor, Nutritional Products for Catalent; and Garnet Pigden, President, Kappa Bioscience, will present “Vitamin K2 Supplements: Combining Science of Product Formulation with Art of Product Design.” Dr. Myers and Mr. Pigden will explain the science behind vitamin K2 in supporting heart health, how ‘ready-to-market’ vitamin K2 formulations can lead to a faster product launch, and discuss new formulations in consumer-preferred dose forms to help marketers drive brand growth and market share.
During the conference, Catalent and Kappa Bioscience will showcase their new product, Cardio K2 Triple Strength Vegicaps® capsules, at the Catalent Booth (#1559), the Kappa Biosciences Booth (#4515), and the GOED (Global Organization for EPA & DHA Omega-3s) pavilion. The capsule combines key ingredients, including Kappa Bioscience’s K2VITAL® product, intended to help promote heart health.
As a recognized authority on natural medicines, Dr. Myers is viewed as one of the world’s top experts in the formulation of dietary supplements and their scientific substantiation. Dr. Myers has formulated complete nutritional lines for global companies and developed many successful products.
At SupplySide West, Catalent will also celebrate the 15-year anniversary of its innovative EasyBurst® chewable technology, aimed at making ingredients such as fish oil more palatable. It will be showcasing the technology at a tasting bar, located at the Catalent booth.
To arrange a meeting with any of the attending Catalent experts at the event, contact Richard Kerns at NEPR – firstname.lastname@example.org
K2VITAL is a registered trademark of Kappa Bioscience AS
Vegicaps is a registered trademark of R.P. Scherer Technologies, LLC
EasyBurst is a registered trademark of Catalent Pharma Solutions, Inc.
Notes for Editors
Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs nearly 13,000 people, including over 2,400 scientists, at more than 35 facilities across five continents, and in fiscal year 2019 generated over $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com